SCHEMBL2656682

SCHEMBL2656682

CCN1Cc2nc3c(-c4cccnc4OC)c(F)ccc3c(N)c2C1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRG2 P18507 7/20 0.36
▸ GABRB3 P28472 7/20 0.36
▸ GABRA2 P47869 7/20 0.36
▸ MTOR P42345 1/20 0.35
▸ ALOX5AP P20292 1/20 0.35
▸ FEN1 P39748 1/20 0.35
▸ METAP2 P50579 1/20 0.34
▸ BTK Q06187 1/20 0.34
▸ PIK3CA P42336 1/20 0.34
▸ PDE5A O76074 3/20 0.34
▸ NPC1 O15118 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ HRH4 Q9H3N8 1/20 0.32
▸ GABRA1 P14867 1/20 0.32
▸ GABRA5 P31644 1/20 0.32
▸ GABRA3 P34903 1/20 0.32
▸ FPR1 P21462 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2656785 0.87 PIK3CA (0.37) GABRG2GABRB3GABRA2MTORMETAP2
SCHEMBL2661635 0.86 GABRG2 (0.49) GABRG2GABRB3GABRA2PDE5A
SCHEMBL2656331 0.86 PDE5A (0.40) GABRG2GABRB3GABRA2PDE5AGABRA1
SCHEMBL2657358 0.85 GABRG2 (0.38) GABRG2GABRB3GABRA2PDE5ATP53
SCHEMBL2661625 0.85 GABRG2 (0.39) GABRG2GABRB3GABRA2MTORALOX5AP
SCHEMBL4923522 0.85 PDE5A (0.34) GABRG2GABRB3GABRA2PDE5AGABRA3
SCHEMBL2661341 0.84 GABRG2 (0.38) GABRG2GABRB3GABRA2METAP2PDE5A
SCHEMBL2655882 0.84 MTOR (0.36) GABRG2GABRB3GABRA2MTORALOX5AP
SCHEMBL2662110 0.83 PIK3CA (0.41) GABRG2GABRB3GABRA2MTORALOX5AP
SCHEMBL2655743 0.83 GABRG2 (0.37) GABRG2GABRB3GABRA2PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF GABRG2 592/4885GABRB3 332/4885GABRA2 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback